Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier functionChristine Jean, David D. Schlaepfer, Xiao Lei Chen et al.|The Journal of Cell Biology|2014Cited by 172
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapyCarlos J. Díaz Osterman, David D. Schlaepfer, Duygu Ozmadenci et al.|eLife|2019Cited by 142
Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Albert Stewart et al.|Journal of Medicinal Chemistry|2017Cited by 129
Distinct FAK-Src activation events promote α5β1 and α4β1 integrin-stimulated neuroblastoma cell motilityLin Wu, David D. Schlaepfer, Joie A. Bernard‐Trifilo et al.|Oncogene|2007Cited by 99
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapyCarlos J. Díaz Osterman, David D. Schlaepfer, Duygu Ozmadenci et al.|bioRxiv (Cold Spring Harbor Laboratory)|2019Cited by 21